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rare case of recurrent primary cutaneous
nodular amyloidosis (PCNA) involving both
sides of the face is being reported from India
where the initial lesion on the right side of face was
operated upon and recurred in 1 year. Around the
same time the patient developed a similar lesion on
the left side. The patient refused any treatment after
being informed about the relatively innocuous na-
ture of the disease. The importance of regular follow-
up was explained to rule out systemic progression.
This is the rarest form of primary cutaneous amyloid-
osis with a very low rate of progression to systemic
amyloidosis. We propose that PCNA be included in
the differential diagnosis of asymptomatic facial
plaques and nodules.CASE REPORT
A 63-year-old man presented with multiple dark
raised lesions on both sides of the face. He had been
operated by a plastic surgeon 8 years prior for a
skin-colored raised lesion on the right side of face
that had developed 12 years earlier and recurred in
1 year. Around the same time he developed similar
lesions on the left mandibular area that gradually
increased in size. There was no history of preceding
trauma. He was a known diabetic and hypertensive
on medication. He denied any other systemic
systems.
On examination, there were well-defined skin-
colored firm nodules, coalescing to form nodulo-
plaques with overlying skin showing absence of hair
on both sides of the face (Fig 1). A linear scar was
visible on the operated site within the plaque that
had recurred. There was no sensory deficit, thick-
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indiaverma@gmail.com.on the body. A biopsy specimen revealed a patchy
nodular deposit of uniformly pink-staining amor-
phous material within the whole of reticular dermis
and extending to septa of subcutaneous fat. The
material was admixed with thickened bundles of
collagen in places whereas at other places it was seen
as closely packed nodules of the deposit that showed
fractured structure (Fig 2). There was no inflamma-
tory infiltrate. The material took up the Congo red
stain (Fig 3). It also showed apple green birefrin-
gence on polarizing microscopy confirming the
diagnosis of cutaneous nodular amyloidosis. The
24-hour urinary protein levels, and urine and serum
protein electrophoresis revealed normal findings.
Antinuclear factor, anti-Ro, and anti-La were normal.
Rheumatoid factor, HIV, and hepatitis B and C
serologies did not show abnormalities. Chest x-ray,
abdominal ultrasonography, and electrocardio-
graphic examination produced normal results. In
view of normal physical examination findings and
the above reports, a diagnosis of PCNA was made.
After being told the nature of the disease and the
expected outcome of various available treatment
modalities, the patient decided to opt for no further
treatment. He, however, agreed to follow-up every
9 months.DISCUSSION
Amyloidosis is considered one of the protein
conformational diseases.1 These are diseases where
specific peptides or proteins do not adopt or remain
in their native functional state and instead get
deposited in various tissues as toxic aggregates.
Amyloid aggregates get deposited in the skin in
various forms of cutaneous amyloidosis.JAAD Case Reports 2016;2:31-3.
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Fig 1. Skin-colored alopecic nodules on the right and left side of the face.
Fig 2. Uniformly pink-staining amyloid throughout the
reticular dermis and admixed with thickened collagen
bundles.
Fig 3. Congo red stain showing pink amyloid material in
the reticular dermis and within thickened collagen
bundles.
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amyloidosis compared with the other 2 types,
macular amyloidosis and lichen amyloidosis.2-4 The
fibrils of amyloid in PCNA are composed of immu-
noglobulin light chains of either kappa and/or
lambda type, called ‘‘protein AL’’ and do not differ
from those seen in primary systemic amyloidosis and
in multiple myeloma.5,6 Unlike in the more common
forms such as macular and lichen amyloidosis where
the amyloid is formed by degenerating keratino-
cytes, monoclonal plasma cells in PCNA produce
and secrete the immunoglobulin kappa and lambda
light chains through an unknown mechanism.2,4,7
Clinically characteristic lesions are single or mul-
tiple asymptomatic nodules and plaques of varyingsizes that may coalesce. There is a predilection for
acral areas including face, scalp, extremities, and
genitalia with majority of lesions occurring on the
face.2,6,8 Because the lesions develop insidiously
they are commonly diagnosed late and the mean
time from onset of lesions to diagnosis is
13.5 years.2,3,6,9 The median age at diagnosis is
57 years (range 24-87 years) with a slight male
predominance. The rarity of the condition is a
limitation to estimate the exact rate of progression
of nodular localized primary cutaneous amyloidosis
(NLPCA) to systemic amyloidosis with estimates
ranging from 7% to 50%.2-4,10 A 1970 study by
Brownstein and Helwig10 reported a rate of 50%, a
figure that was quoted by many.2 However, since
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overestimate. Fifteen cases of NLPCA by Woollons
and Black2 have shown the risk of progression of
NLPCA to be as low as 7%. In a review of articles
describing a total of 65 patients with NLPCA, only 1
patient had progressed to systemic amyloidosis.8
Most other literature also suggests that the risk of
progression is low but the patient be followed up
regularly. There is extensive and diffuse amyloid
deposit in deeper parts of the dermis, subcutaneous
tissue, and the small dermal blood vessels unlike in
the more common forms such as macular amyloid-
osis and lichen amyloidosis.2,4,5,8,10 All of the
amyloid material appears as homogenous and
eosinophilic in hematoxylin-eosin stain and shows
up as a pinkish amorphous mass in more specific
stains such as Congo red.
It is imperative to rule out systemic involvement
because morphologically identical lesions are found
both in primary and systemic amyloidosis.2,5,6 There
is a strong body of evidence to suggest a
genetic basis to development and progression of
amyloidosis. Mutations such as oncostatin M
receptor-beta on chromosome 5p13.1 and/or
interleukin-31 receptor A on the same chromosome
have also been documented.11,12
Investigations recommended for ruling out
systemic involvement include complete blood cell
count with differential and platelet count, serum
calcium, blood urea nitrogen, and S creatinine.
Serum protein electrophoresis, urine protein
electrophoresis and 24-hour urine protein are carried
out for multiple myeloma. Ideally, as is practiced in
advanced countries, quantitative immunoglobulin
levels, serum free light chain, immunofixation, and
cytogenetics including fluorescence in situ hybridi-
zation should be done but these are prohibitively
expensive in India where the average dermatology
patient pays for all his medical expenses out of his
own pocket and hence these were not done. Other
supplementary investigations should include lipid
profile, liver function tests, HIV serology, hepatitis B
and C serology, chest x-ray, abdominal ultrasonog-
raphy, and electrocardiogram. Because a significant
number of cases of PCNA are associated with Sj€ogren
syndrome, serology should include antinuclear
antibodies, anti-Ro/SSA and anti-La/SSB.2,5
There is a tendency for PCNA to recur after
attempted intervention. One large study estimates it
at 9%.8 Various modalities to change the appearance
of the lesions include topical and intralesional
steroids, dermabrasion, cryotherapy, curettage and
electrodessication, and excisional surgery.2,3,5,9Laser modalities such as carbon-dioxide and pulse-
dye laser have been tried but lesions tend to recur.2,3
More important seems to be meticulous follow-up of
the patient in 6 to 12 months to rule out progression
of PCNA to a systemic form of amyloidosis.2,3,8
Investigations done for this are the same as the
ones mentioned earlier. Some centers also
recommend periumbilical fat tissue aspiration and
rectal pad biopsy for immunochemical analysis of
specific amyloid proteins and their quantification.
Our documentation of this rare condition is rendered
more interesting by the fact that our patient had
bilateral lesions and the original one recurred
after surgery followed by a lesion on the other side
after many years. Trauma of the previous surgery
may have led to recurrence as the condition is
known to be associated with trauma.4 We propose
that PCNA be always included in the differential
diagnosis of nodular or plaque-type lesions
occurring on the face.
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